Abstract
Cardiovascular disease is the most prevalent cause of death in patients with chronic kidney disease (CKD), even at an early stage of the disease and is considered a coronary heart disease risk equivalent. Therefore, therapeutic efforts to control modifiable additional cardiovascular risk factors such as dyslipidemia in this population seems reasonable. Indeed, abnormalities of lipid metabolism are often encountered in patients with CKD, end stage renal disease or after kidney transplantation. In this review we will summarize the currently available data on etiology, epidemiology, and impact on cardiovascular morbidity in patients with CKD, renal pathologies like the nephrotic syndrome and after kidney transplantation and give a brief overview of the existing guidelines on treating dyslipidemia.
Keywords: Dyslipidemia, chronic kidney disease, cardiovascular risk, statin, etiology, urinalysis, nephropathy, hematuria, glycaemia, acetosalicylic acid, polysulfone, unequivocally, lipiduria, tubulointerstitial, mesangioproliferative, rapamycin, mycophenolate, calcineurin, sirolimus
Current Pharmaceutical Design
Title: Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient
Volume: 17 Issue: 9
Author(s): Volker Burst and Thomas Benzing
Affiliation:
- Renal Division, Department of Medicine, University of Cologne Kerpener Str. 62, 50937 Cologne, Germany.,Germany
Keywords: Dyslipidemia, chronic kidney disease, cardiovascular risk, statin, etiology, urinalysis, nephropathy, hematuria, glycaemia, acetosalicylic acid, polysulfone, unequivocally, lipiduria, tubulointerstitial, mesangioproliferative, rapamycin, mycophenolate, calcineurin, sirolimus
Abstract: Cardiovascular disease is the most prevalent cause of death in patients with chronic kidney disease (CKD), even at an early stage of the disease and is considered a coronary heart disease risk equivalent. Therefore, therapeutic efforts to control modifiable additional cardiovascular risk factors such as dyslipidemia in this population seems reasonable. Indeed, abnormalities of lipid metabolism are often encountered in patients with CKD, end stage renal disease or after kidney transplantation. In this review we will summarize the currently available data on etiology, epidemiology, and impact on cardiovascular morbidity in patients with CKD, renal pathologies like the nephrotic syndrome and after kidney transplantation and give a brief overview of the existing guidelines on treating dyslipidemia.
Export Options
About this article
Cite this article as:
Burst Volker and Benzing Thomas, Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient, Current Pharmaceutical Design 2011; 17(9) . https://dx.doi.org/10.2174/138161211795428867
DOI https://dx.doi.org/10.2174/138161211795428867 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report
Current Vascular Pharmacology The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Aspect of Beta-Thalassaemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiology of Coronary Thrombus Formation and Adverse Consequences of Thrombus During PCI
Current Cardiology Reviews Pharmacologic Approach to Heart Failure in Children
Current Cardiology Reviews Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Focus on Virus Induced Exacerbations
Current Pharmaceutical Design Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Subject Index to Volume 2
Current Vascular Pharmacology Triggers and Anatomical Substrates in the Genesis and Perpetuation of Atrial Fibrillation
Current Cardiology Reviews A Combination of 3D-QSAR Modeling and Molecular Docking Approach for the Discovery of Potential HIF Prolyl Hydroxylase Inhibitors
Medicinal Chemistry Medicinal Chemistry Approaches for Glucokinase Activation to Treat Type 2 Diabetes
Current Medicinal Chemistry